Cancer Therapy News and Research

RSS

Breast cancer symposium to discuss on latest advances in research and treatment

The latest advances in both breast cancer treatment and research - including innovations in diagnostic, surgical, chemotherapy and radiation approaches - will be discussed Friday, April 8, 2011, at a breast cancer symposium at the Kimmel Cancer Center at Jefferson in Philadelphia.

7 Apr 2011

Fish oil can serve as beneficial booster for tamoxifen breast cancer therapy

Breast cancer is the second most common cancer among women, with more than 200,000 women diagnosed each year. Being exposed to estrogen over a long period of time is one factor that can increase a woman's risk of developing the disease.

7 Apr 2011

Circadian's VGX-100 neutralises VEGF-C and inhibits tumour growth in mouse models of human cancers

Circadian Technologies Limited today released data at the American Association for Cancer Research (AACR) annual conference in Orlando, Florida (U.S.A.) demonstrating that its lead anti-cancer therapeutic, VGX-100, significantly inhibits tumour growth and spread in a variety of different mouse models of human cancer.

7 Apr 2011

VBL's VB-111 preclinical data against metastatic cancer presented at AACR meeting

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced preclinical data demonstrating VB-111's potential utility as a targeted cancer treatment.

7 Apr 2011

Superbugs and antibiotic resistance

Health experts come together today (Thursday) to warn that a new form of superbug that gives bacteria the power to resist virtually all known antibiotics is spreading quickly, posing a global health disaster. It is called New Delhi metallobeta-lactamase, or NDM-1 for short. This enzyme destroys carbapenems, an important group of antibiotics used for difficult infections in hospitals, and has been found in a wide variety of bacterial types. British researchers last August reported that infections involving NDM-1 had been found in patients in Bangladesh, India, Pakistan and Britain.

6 Apr 2011

Record number of medicines for various cancers in clinical trials

A record 887 medicines for various of cancers are in clinical trials or awaiting Food and Drug Administration (FDA) review—well over double the number in the pipeline just six years ago, according to a report unveiled today by the Pharmaceutical Research and Manufacturers of America (PhRMA).

6 Apr 2011

Specific lipids in tumours linked to cancer progression and patient survival

Activation of lipid metabolism is an early event in carcinogenesis and a central hallmark of many cancers. However, the precise molecular composition of lipids in tumours remains generally poorly characterised. Scientists from VTT Technical Research Centre of Finland and the Charité Hospital have found lipids in tumours which are associated with cancer progression.

6 Apr 2011

Soy food does not increase risk of recurrence or death among breast cancer survivors

Soy food consumption did not increase the risk of cancer recurrence or death among survivors of breast cancer, according to the results of a study presented at the AACR 102nd Annual Meeting 2011, held April 2-6.

6 Apr 2011

Keryx KRX-0401 data in colorectal cancer, multiple myeloma presented at AACR meeting

Keryx Biopharmaceuticals, Inc. today announced that two posters on KRX-0401 were presented at the 102nd annual meeting of the American Association for Cancer Research currently ongoing at the Orange County Convention Center in Orlando, Florida. Perifosine, the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, is currently in Phase 3 clinical trials for refractory advanced colorectal cancer and multiple myeloma.

6 Apr 2011

Aeterna Zentaris presents two posters on perifosine at AACR meeting

Aeterna Zentaris Inc. today announced that two posters on its lead anticancer agent, perifosine, were presented at the 102nd annual meeting of the American Association for Cancer Research currently held at the Orange County Convention Center in Orlando, Florida.

5 Apr 2011

Synta presents ganetespib and elesclomol study data in cancer at AACR meeting

Synta Pharmaceuticals Corp. today presented five posters at the American Association for Cancer Research 102nd Annual Meeting. Three posters reported results from studies of ganetespib, and two posters reported results from studies of elesclomol, a small-molecule mitochondria metabolism inhibitor.

5 Apr 2011

Artemisinin or high-pressure oxygen can boost natural cancer remedy

A technique Michael Jackson reportedly used to prolong his youth is showing promise as a way to boost the effectiveness of a natural cancer remedy.

5 Apr 2011

American Cancer Society awards 85 institutions with $49,213,000 for new research, training

The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 132 national research and training grants totaling $49,213,000 to 85 institutions nationwide in the second of two grants cycles for 2011.

5 Apr 2011

Curis presents vismodegib Phase II data in basal cell nevus syndrome at AACR meeting

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the presentation of interim Phase II clinical data on Hedgehog pathway inhibitor vismodegib in patients with basal cell nevus syndrome, which is also commonly referred to as Gorlin syndrome.

5 Apr 2011

Researchers develop new cancer treatment

Scientists from the School of Pharmacy at Queen's University Belfast and Almac Discovery Ltd have developed a new treatment for cancer which rather than attacking tumours directly, prevents the growth of new blood vessels in tumours, starving them of oxygen and nutrients, thereby preventing their growth.

5 Apr 2011

Lilly presents results of JAK2, Hedgehog inhibitor preclinical cancer studies at 102nd AACR

Eli Lilly and Company announced results today from two preclinical studies of molecules that target genetic mutations and disable specific signaling pathways that can lead to cancer. The studies evaluated two unique molecules – a JAK2 inhibitor and a Hedgehog inhibitor – with results presented during the American Association for Cancer Research (AACR) 102nd Annual Meeting in Orlando, Fla.

5 Apr 2011

New anti-angiogenic therapy can lead to tumour growth inhibition

Scientists from the School of Pharmacy at Queen's University Belfast and Almac Discovery Ltd, announce the first publication describing a potential new anti-angiogenic therapy based on a natural protein first discovered at QUB. Anti-angiogenics prevent the growth of new blood vessels in tumours and starve them of nutrients, leading to inhibition of tumour growth.

4 Apr 2011

Men who consume digoxin have 24% reduced risk of prostate cancer

Johns Hopkins scientists and their colleagues paired laboratory and epidemiologic data to find that men using the cardiac drug, digoxin, had a 24 percent lower risk for prostate cancer. The scientists say further research about the discovery may lead to use of the drug, or new ones that work the same way, to treat the cancer.

4 Apr 2011

Scientists identify new treatment target for squamous cell lung cancer

Scientists at the Dana Farber Cancer Institute have identified a mutation in the DDR2 gene that may indicate which patients with squamous cell lung cancer will respond to dasatinib.

4 Apr 2011

Scientists identify digoxin as possible therapy for prostate cancer

Scientists have identified digoxin as a possible therapy for prostate cancer, using a combination of laboratory science and epidemiology that is unprecedented in its cooperative nature.

4 Apr 2011

Cancer Therapy News and Research

Breast cancer symposium to discuss on latest advances in research and treatment

Fish oil can serve as beneficial booster for tamoxifen breast cancer therapy

Circadian's VGX-100 neutralises VEGF-C and inhibits tumour growth in mouse models of human cancers

VBL's VB-111 preclinical data against metastatic cancer presented at AACR meeting

Superbugs and antibiotic resistance

Record number of medicines for various cancers in clinical trials

Specific lipids in tumours linked to cancer progression and patient survival

Soy food does not increase risk of recurrence or death among breast cancer survivors

Keryx KRX-0401 data in colorectal cancer, multiple myeloma presented at AACR meeting

Aeterna Zentaris presents two posters on perifosine at AACR meeting

Synta presents ganetespib and elesclomol study data in cancer at AACR meeting

Artemisinin or high-pressure oxygen can boost natural cancer remedy

American Cancer Society awards 85 institutions with $49,213,000 for new research, training

Curis presents vismodegib Phase II data in basal cell nevus syndrome at AACR meeting

Researchers develop new cancer treatment

Lilly presents results of JAK2, Hedgehog inhibitor preclinical cancer studies at 102nd AACR

New anti-angiogenic therapy can lead to tumour growth inhibition

Men who consume digoxin have 24% reduced risk of prostate cancer

Scientists identify new treatment target for squamous cell lung cancer

Scientists identify digoxin as possible therapy for prostate cancer

Event guide: 7th Allogeneic Cell Therapies Summit eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News